Art manager

Acclaimed Project Leader Megan Euker Wins Coveted SAN ROCCO THERAPEUTICS (SRT) Award Announces

Megan Euker, photo by Ian Fisher

Installation Shot, “The Cure” exhibition by Megan Euker at the International Museum of Surgical Science Chicago, photo by James Prinz

Past winners of the awards include 60 Nobel laureates, 88 Pulitzer Prize winners and 39 who have served as heads of state or government.

LOS ANGELES, CA, USA, July 15, 2022 / — Acclaimed project leader Megan Euker receives the Fulbright US Scholar Award in Sicily for her work with the development of SRT gene therapy for sickle cell disease and beta-thalassemia. Fulbright alumni include 60 Nobel Prize winners, 88 Pulitzer Prize winners, and 39 who have served as heads of state or government.

San Rocco Therapeutics, founded in 1993, has been collaborating with Megan Euker since 2016. Euker is also affiliated with the School of the Art Institute of Chicago and the University of South Florida. She will conduct research and teach at MADE in Syracuse, Sicily, as part of her “Sangue Tira (Blood Pulls)” project. Euker will help SRT advance its gene therapy, adding an insulator for increased patient safety.

Although there have been no adverse effects during the nine years of follow-up of patients treated with SRT gene therapy, the company is collaborating with institutions and researchers, including Dr. Chris Ballas of Innovative Cellular Therapeutics; Dr. Andrew Wilber of Southern Illinois University; and Dr. Frank Park of the University of Tennessee, to improve the safety and efficacy of his vector. In February 2022, Dr. Michel Sadelain, the inventor of SRT therapy, published the importance of an insulator to decrease the likelihood of disrupting neighboring genes.

SRT plans to charge $700,000 per patient, or one-third the cost of Bluebird Bio’s projected price. With the likely approval of Bluebird Bio’s gene therapy for sickle cell disease and thalassemia, SRT believes its vector is a wiser and safer option for patients.

In the interest of patients, San Rocco has filed lawsuits against Bluebird Bio, Third Rock Ventures and Memorial Sloan Kettering Cancer Center. In the Delaware litigation, SRT filed patent infringement actions against Bluebird Bio and Third Rock Ventures. In the Southern District of New York (SDNY) litigation, SRT originally filed a declaratory judgment action with the SDNY. Subsequently, SRT added unfair competition and fraudulent inducement claims against MSK.

The story of San Rocco Therapeutics and its challenges against Big Pharma has just been published in Patrick Girondi’s (SRT Founder) book Flight of the Rondone: High School Dropout VS Big Pharma: The Fight to Save My Son’s Life.

Girondi’s book was featured as a #1 Wall Street Journal bestseller the first week of July 2022 in addition to reaching #1 on three Amazon bestseller lists; #1 on Barnes and Noble; and top 100 on USA Today. It provides insight into the diagnosis of his first son’s thalassemia, navigating the healthcare system in the United States and Europe, and devoting the past thirty years to curing the world’s two most common inherited blood diseases. The company hopes to begin clinical trials with the improved vector in 2023.



Aurora Of Rose
Media Unlimited Inc.
9518700099 ext.
write to us here